C4 Therapeutics, Inc.
CCCC · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 31.10M | 31.10M | -129.53M | -128.18M | -2.62 |
| 2023 FY | 20.76M | 13.02M | -139.03M | -132.49M | -2.67 |
| 2024 FY | 35.58M | 35.58M | -119.61M | -105.32M | -1.52 |
| 2025 FY | 35.95M | 27.97M | -104.49M | -104.99M | -1.27 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 430.84M | 141.61M | 29.75M | 87.15M | 289.23M |
| 2023 FY | 376.45M | 130.34M | 126.59M | 70.98M | 246.11M |
| 2024 FY | 349.60M | 133.62M | 55.50M | 65.76M | 215.99M |
| 2025 FY | 359.08M | 102.49M | 74.60M | 59.98M | 256.59M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -105.94M | -5.50M | -111.44M | — | -46.37M |
| 2023 FY | -106.84M | -1.71M | -108.55M | — | 97.00M |
| 2024 FY | -65.16M | -180.00K | -65.34M | — | -71.09M |
| 2025 FY | -98.69M | -607.00K | -99.30M | — | 19.10M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 288.28M | 345.68M | — | — | — |
| 2023 FY | 280.47M | 224.85M | — | — | — |
| 2024 FY | 249.74M | 260.00M | — | — | — |
| 2025 FY | 158.33M | 143.71M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 6.46M | 6.46M | -28.50M | -26.02M | -0.37 |
| 2025 Q3 | 11.23M | 11.23M | -34.41M | -32.17M | -0.44 |
| 2025 Q4 | 11.02M | 11.02M | -23.15M | -20.49M | -0.18 |
| 2026 Q1 | 6.15M | 4.35M | -27.79M | -25.13M | -0.20 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 296.53M | 122.46M | 78.16M | 62.92M | 174.06M |
| 2025 Q3 | 265.49M | 111.08M | 58.81M | 61.46M | 154.41M |
| 2025 Q4 | 359.08M | 102.49M | 74.60M | 59.98M | 256.59M |
| 2026 Q1 | 328.86M | 94.61M | 61.27M | 58.45M | 234.25M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -12.06M | -185.00K | -12.24M | — | 26.86M |
| 2025 Q3 | -31.21M | -411.00K | -31.62M | — | -19.35M |
| 2025 Q4 | -22.15M | -11.00K | -22.16M | — | 15.79M |
| 2026 Q1 | -29.94M | -64.00K | -30.01M | — | -13.33M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 101.54M | 86.30M | — | — | — |
| 2025 Q3 | 161.09M | 163.74M | — | — | — |
| 2025 Q4 | 223.06M | 208.44M | — | — | — |
| 2026 Q1 | 331.58M | 328.75M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |